Otezla and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data

Summary:

Paranasal sinus hypersecretion is reported as a side effect among people who take Otezla (apremilast), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin D3, and have Psoriasis.

The phase IV clinical study analyzes which people have Paranasal sinus hypersecretion when taking Otezla. It is created by eHealthMe based on reports of 146,032 people who have side effects when taking Otezla from the FDA, and is updated regularly.

What is Otezla?

Otezla has active ingredients of apremilast. It is often used in psoriatic arthritis. eHealthMe is studying from 146,254 Otezla users. Check the latest studies of Otezla.

What is Paranasal sinus hypersecretion?

Paranasal sinus hypersecretion is found to be associated with 438 drugs and 462 conditions by eHealthMe. Check the latest studies of Paranasal sinus hypersecretion.

On Jul, 14, 2026

146,032 people reported to have side effects when taking Otezla.
Among them, 23 people (0.02%) have Paranasal sinus hypersecretion.

Could Otezla cause Paranasal sinus hypersecretion?

Among these 23 people:

How long have people been on Otezla when they have Paranasal sinus hypersecretion? *

What is the gender of people who have Paranasal sinus hypersecretion when taking Otezla? *

female: 73.91 %
male: 26.09 %

What is the age of people who have Paranasal sinus hypersecretion when taking Otezla? *

What are other drugs people take besides Otezla? *

What are other side effects people have besides Paranasal sinus hypersecretion? *

Diarrhea: 11 people, 47.83%
Headache (pain in head): 7 people, 30.43%
Nausea (feeling of having an urge to vomit): 7 people, 30.43%
Weight Decreased: 4 people, 17.39%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 17.39%
Weakness: 4 people, 17.39%
Nausea And Vomiting: 4 people, 17.39%
Oropharyngeal Pain: 3 people, 13.04%
Cough: 3 people, 13.04%
Eye Pain: 3 people, 13.04%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 13 people, 56.52%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 26.09%
Barrett's Oesophagus (barrett's oesophagus is a disorder in which the lining of the oesophagus (the tube that carries food from the throat to the stomach) is damaged by stomach acid and changed to a lining similar to that of the stomach): 2 people, 8.70%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 8.70%
Oesophageal Disorder (disease of oesophagus): 2 people, 8.70%
Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 8.70%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 4.35%
Hypersensitivity: 1 person, 4.35%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 1 person, 4.35%
Depression: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Otezla and have Paranasal sinus hypersecretion?

- Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Otezla:

Otezla (146,254 reports)

Browse all side effects of Otezla:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (438 drugs)

Browse all the conditions that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (462 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on apremilast (the active ingredients of Otezla) and Otezla (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.